PatientsVille.com Logo

Hypertrichosis and Nair

PatientsVille

Hypertrichosis Symptoms and Causes

The average person has 5 million hairs. Hair grows all over your body except on your lips, palms, and the soles of your feet. It takes about a month for healthy hair to grow half an inch. Most hairs grow for up to six years and then fall out. New hairs grow in their place.

Hair helps keep you warm. It also protects your eyes, ears and nose from small particles in the air. Common problem with the hair and scalp include hair loss, infections, and flaking.

Check out the latest treatments for hypertrichosis

hypertrichosis treatment research studies

Nair clinical trials, surveys and public health registries


Find Drug Side Effect reports



Nair Side Effects

Pain (14)
Swelling (8)
Burning Sensation (7)
Blister (6)
Application Site Burn (6)
Application Site Irritation (5)
Skin Infection (3)
Skin Disorder (3)
Skin Tightness (3)
Pruritus (1)
Eye Swelling (1)
Application Site Pruritus (1)
Erythema (1)
Paraesthesia (1)
Product Lot Number Issue (1)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

I had a really bad experience with Naire, unfortunately I've never used it before quiet frankly I was utterly disappointed. I applied it on my legs and my privates and left it to sit for no more than 2-3 minutes. After rinsing off, and patting dr

I have been useing nair for five years now. It does burn if you leave it on longer then 3three min.that only the first few times. but after a while your body get use to it, it doesn.t mean you should keep it on longer Know 3-4 min is good enough. but

I used it on my vagina then it got swollen

I used nair on my pubic are at it is now constantly red. There was no burning sensation, nor was there any bumps or swelling. I did not experience any pain, but my skin is still red on the area that i used it. what can I do? I have tried various crea

I used nair on my vagina and now it burns so much! what should i do?!? please help, hurts loads :(

I used nair yesterday twice in the same place because It didn't take out all the hair's the first time and later on that night my skin got irritated and is still irritated what can I got on it for the redness to go away and the bumps

I used naire lotion on my vagina area and now it burns when i pee.It also burned my skins down there and it is very red and a little swollen on the lips of my vagina area.

I used the nair bikini area cream and my skin is raw,red and pussing. It was only on for 2 min before it started burn. I am in pain and I can't wear a bathsuit. I am a AA female with a wide raw red puss bikini area. I am treating it with A &

I've just started using Vannair and want to research any side effects.

My vagina is swollen and red, I feel discomfort when I pee. What can I do to soothe my area

Hypertrichosis Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Not yet recruiting Early Conversion From CNI to Belatacept in Renal Transplant Recipients With Delayed and Slow Graft Function
Conditions: Delayed Graft Function;   Kidney Transplant
Interventions: Drug: Belatacept;   Drug: Calcineurin Inhibitor
Outcome Measures: cGFR;   Renal Histology;   Biomarker profile;   Duration of Delayed (or slow) Graft Function;   Incidence of Acute Rejection;   New Onset Diabetes;   Blood Pressure Control;   Dyslipidemia;   Graft Survival;   Patient survival
2 Not yet recruiting Study of the Prednisone Sparing Effect of Xolair (Omalizumab) in Patients With Prednisone-dependent Asthma With Eosinophilic Bronchitis
Conditions: Prednisone Dependent Asthma;   Eosinophilic Bronchitis
Interventions: Biological: Omalizumab (Xolair);   Drug: Placebo
Outcome Measures: proportion of patients with exacerbations in each study group from week 0 to week 32.;   the magnitude of the reduction in the dose of prednisone from week 12 to week 32.;   change in % sputum eosinophil;   Blood eosinophils;   Forced Expired Volume in 1 second (FEV1);   Ratio of Forced Expired Volume in 1 second to Forced Vital Capacity (FEV1/VC);   Provocative concentration causing a 20% drop in FEV1 (PC20);   Asthma Control QuestionNaire;   Fraction of exhaled nitric oxide (FeNO)
3 Recruiting "Effect of High Fat and High Glycemic Diets
Condition: Type 2 Diabetes
Interventions: Behavioral: High Glycemic Diet;   Behavioral: Control diet
Outcome Measures: Insulin Sensitivity;   ceramides and diacylglycerol
4 Recruiting The Use of Intranasal Ketoralac for Pain Management
Conditions: Postoperative Pain Management;   Urolithiasis
Interventions: Drug: Intranasal Ketoralac;   Drug: Placebo
Outcome Measures: Post-operative opioid requirements;   Post operative pain score
5 Recruiting Project Grow Smart: Intervention Trial of Multiple Micronutrients and Early Learning Among Infants in India
Conditions: Nutritional Deficiencies;   Developmental Delay
Interventions: Dietary Supplement: Micronutrient Intervention;   Behavioral: Early Learning
Outcome Measures: Change in cognitive, language, motor, and socio-emotional development;   Change in micronutrient Status
6 Not yet recruiting Augmented Wide Area Circumferential Catheter Ablation for Reduction of Atrial Fibrillation Recurrence
Condition: Atrial Fibrillation
Interventions: Procedure: Wide area circumferential catheter ablation;   Procedure: Augmented- wide area circumferential ablation procedure
Outcome Measures: Recurrence of any ECG documented AF, AFl or AT;   repeat catheter ablation procedure;   ECG documented AF;   emergency department visits or hospitalizations;   procedure related complications;   Quality of Life
7 Recruiting Mepolizumab in Chronic Obstructive Pulmonary Diseases (COPD) With Eosinophilic Bronchitis
Conditions: Chronic Obstructive Pulmonary Diseases;   Chronic Airways Limitation;   Bronchitis
Interventions: Drug: Mepolizumab;   Drug: placebo
Outcome Measures: Percentage decrease of sputum eosinophils from baseline;   Proportion of patients with a major exacerbation
8 Unknown  A Multi-site, Individually Randomized, Controlled Translation Trial of Integrated and Comprehensive Care Strategies to Reduce Cardiovascular Disease (CVD) Risk Among 1,120 Type 2 Diabetes Mellitus(T2DM) Patients in South Asia
Conditions: Type 2 Diabetes Mellitus;   Hypertension;   Dyslipidaemia
Interventions: Other: Care Coordinator + Decision Support Software;   Other: Usual care
Outcome Measures: Multiple CVD risk factor control targets;   Single risk factor control of at least one target either HbA1c or blood pressure or LDL-Cholesterol;   The cost effectiveness analysis of the intervention compared to the usual care.;   Quality of life;   Prescriber and patient acceptability of the Digital Support software and care coordinator with management guidelines.
9 Recruiting Cyclophosphamide and Busulfan as Conditioning Regimen Before Allogeneic HSCT
Conditions: Myeloid Leukemia;   Precursor Myeloid Neoplasms;   Lymphoid Neoplasms
Interventions: Drug: Busulfan-Cyclophosphamide as Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide-Busulfan as Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation
Outcome Measures: Liver toxicity;   VOD;   Acute graft-versus-host disease (GvHD);   Toxicity;   Efficacy;   Cumulative liver values;   Maximum liver values
10 Recruiting Anesthetic Technique for AV Fistulae Creation
Condition: End Stage Renal Failure on Dialysis
Interventions: Procedure: regional anesthesia;   Procedure: local anesthesia
Outcome Measures: AV fistula success rate;   Short term comfort level;   Short term safety, number of post operative complications
11 Not yet recruiting Anti-arrhythmic Therapy vs Catheter Ablation as First Line Treatment for AICD Shock Prevention
Conditions: Ventricular Tachycardia;   Ventricular Arrhythmia
Interventions: Drug: Antiarrhythmic Drug Therapy;   Procedure: Catheter ablation
Outcome Measures: Appropriate ICD therapy;   Composite Safety Endpoint
12 Recruiting Effects of Calorie Restriction on Accumulation of Old, Modified Proteins in Abdominally Obese Adults
Condition: Insulin Resistance
Interventions: Behavioral: Calorie Restriction;   Behavioral: Control (normal living)
Outcome Measures: Change in muscle protein synthesis from baseline to 16 weeks;   Change in insulin sensitivity from 0 (baseline) and 16 weeks
13 Recruiting Effects of Aerobic and Resistance Training on Accumulation of Old, Modified Proteins in Young and Older Adults
Condition: Sarcopenia
Interventions: Behavioral: High intensity aerobic exercise;   Behavioral: Resistance exercise training;   Behavioral: Combined
Outcome Measure: Skeletal muscle protein synthesis rate
14 Recruiting A Study of an Oral Nutrition Supplement (ONS) in Children.
Condition: Growth
Interventions: Other: Nutrition supplement + dietary counseling;   Other: Dietary Counseling
Outcome Measures: Weight;   Respiratory Infections;   Sick Days;   Doctor Visits;   Dietary Intake;   Appetite Score
15 Unknown  Safety and Activity of ORE1001 in Subjects With Ulcerative Colitis
Condition: Mild to Moderate Ulcerative Colitis
Interventions: Drug: ORE1001;   Drug: Placebo
Outcome Measures: The safety and tolerability of ORE1001 in subjects with ulcerative colitis as demonstrated by the frequency and severity of adverse events;   Change in the modified Baron Score from Baseline to Week 6;   Change in the Ulcerative Colitis Clinical Score from Baseline;   Change in the partial Mayo Score fom baseline;   Calprotectin concentrations;   Riley Acute Inflammation Scale (histology);   Clinical remission
16 Recruiting To Compare the Efficacy and Safety of Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel of CHL Versus DUAC® Gel
Condition: Acne Vulgaris
Interventions: Drug: Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel;   Drug: DUAC® Gel;   Drug: Placebo
Outcome Measures: Mean percent change from baseline to week 11 (study Day 77) for inflammatory (papules and pustules) lesions.;   Mean percent change from baseline to week 11 in the non-inflammatory lesion count;   Proportion of subjects with a clinical response of "success" at week 11
17 Recruiting Phase 3 Bovine Rotavirus Vaccine in India
Condition: Rotavirus Gastroenteritis
Interventions: Biological: Vaccine Live Attenuated Pentavalent (G1-G2-G3-G4-G9) Human X Bovine Reassortant Rotavirus Vaccine (BRV-PV);   Other: Placebo
Outcome Measures: occurrence of Severe Rotavirus Gastroenteritis;   Safety
18 Not yet recruiting Tenofovir Levels Following Local Application of Tenofovir Reduced-Glycerin 1% Gel
Condition: HIV Prevention
Interventions: Drug: Once Daily Application of TFV RG 1% Gel;   Drug: Once Daily Application of TFV RG 1% gel - Rectal;   Drug: Once Daily Application of TFV RG 1% Gel - Vaginal
Outcome Measures: Drug concentrations;   Number of adverse events Grade 2 or higher
19 Recruiting <Metformin's Effect on Glucagon-induced Glucose Production and Protein Metabolism.
Conditions: Insulin Resistance;   Prediabetic State
Interventions: Drug: Metformin;   Drug: Placebo
Outcome Measures: Change in Glucagon-induced endogenous glucose production.;   Change in glucagon-induced alterations in whole body protein metabolism and resting energy expenditure.
20 Recruiting Efficacy and Safety Study of Benralizumab to Reduce OCS Use in Patients With Uncontrolled Asthma on High Dose Inhaled Corticosteroid Plus LABA and Chronic OCS Therapy
Condition: Asthma
Interventions: Biological: Benralizumab;   Biological: Placebo
Outcome Measures: The effect of 2 dosing regimens of benralizumab on percentage reduction of Oral Corticosteroid dose in the terms of percentage reduction in final Oral Corticosteroid dose compared with week 0, while maintaining asthma control;   The effect of 2 dosing regimens of benralizumab on Oral Corticosteroid dose in the terms of proportion of patients with ≥50% reduction in average daily Oral Corticosteroid dose at week 28 compared with dose at week 0 while maintaining asthma control;   The effect of 2 dosing regimens of benralizumab on Oral Corticosteroid dose in the terms of proportion of patients with average final Oral Corticosteroid dose ≤5.0 mg daily at week 28, while maintaining asthma control.;   The effect of 2 dosing regimens of benralizumab on Oral Corticosteroid dose in the terms of proportion of patients with ≤5.0 mg reduction on daily Oral Corticosteroid dose at week 28 compared with dose at week 0, while maintaining asthma control.;   The effect of 2 dosing regimens of benralizumab on parameters associated with asthma exacerbations in the terms of proportion of patients with ≥1 asthma exacerbation after randomization;   The effect of 2 dosing regimens of benralizumab on parameters associated with asthma exacerbations in the terms of time to the first asthma exacerbation after randomization;   The effect of 2 dosing regimens of benralizumab on parameters associated with asthma exacerbations in the terms of annual rate of asthma exacerbations that are associated with an emergency room visit or a hospitalization after randomization;   The effect of 2 dosing regimens of benralizumab on pulmonary function in the terms of change from week 0 in prebronchodilator Forced Expiratory Volume in 1 second (FEV1);   The effect of 2 dosing regimens of benralizumab on pulmonary function in the terms of change from week 0 in prebronchodilator Inspiratory Capacity (IC).;   The effect of 2 dosing regimens of benralizumab on pulmonary function in the terms of change from week 0 in Expiratory Reserve Volume (ERV).;   The effect of 2 dosing regimens of benralizumab on pulmonary function in the terms of change from week 0 in Inspiratory Reserve Volume (IRV).;   The effect of 2 dosing regimens of benralizumab on pulmonary function in the terms of change from week 0 in Inspiratory Vital Capacity (VCIN).;   The effect of 2 dosing regimens of benralizumab on pulmonary function in the terms of change from week 0 in Expiratory Vital Capacity (VCEX).;   The effect of 2 dosing regimens of benralizumab on pulmonary function in the terms of change from week 0 in Maximum Vital Capacity (VCMAX).;   The effect of 2 dosing regimens of benralizumab on asthma symptoms and other asthma control metrics in the terms of change from week 0 in asthma symptom score (total, daytime, and night time).;   The effect of 2 dosing regimens of benralizumab on asthma symptoms and other asthma control metrics in the terms of change from week 0 in rescue medication use.;   The effect of 2 dosing regimens of benralizumab on asthma symptoms and other asthma control metrics in the terms of change from week 0 in home lung function (morning and evening Peak Expiratory Flow (PEF)).;   The effect of 2 dosing regimens of benralizumab on asthma symptoms and other asthma control metrics in the terms of change from week 0 in the number of nights with awakening due to asthma requiring rescue medication.;   The effect of 2 dosing regimens of benralizumab on asthma symptoms and other asthma control metrics in the terms of change from week 0 in Asthma Control QuestionNaire 6 (ACQ-6).;   The effect of 2 dosing regimens of benralizumab on asthma related health-related quality of life in the terms of change from week 0 in Standardised Asthma Quality of Life QuestionNaire for 12 Years and Older (AQLQ(S)+12).;   The pharmacokinetics (PK) of 2 dosing regimens of benralizumab in the terms of PK parameters;   The immunogenicity of 2 dosing regimens of benralizumab in the terms of Anti-drug antibodies (ADA) presence or absence;   The safety and tolerability of 2 dosing regimens of benralizumab in the terms of Adverse Event (AE)/Serious Adverse Event (SAE);   The safety and tolerability of 2 dosing regimens of benralizumab in the terms of laboratory variables;   The safety and tolerability of 2 dosing regimens of benralizumab in the terms of electrocardiogram (ECG) evaluation;   The safety and tolerability of 2 dosing regimens of benralizumab in the terms of physical examination results;   The impact of 2 dosing regimens of benralizumab on blood eosinophil count.;   The impact of 2 dosing regimens of benralizumab on blood eosinophil levels (subset of patients) in the terms of assessment of eosinophil progenitor cells;   The impact of 2 dosing regimens of benralizumab on sputum differential cell count (subset of patients) in the terms of sputum cell differential count;   The impact of 2 dosing regimens of benralizumab on biomarkers (subset of patients) in the terms of quantification of sputum cytokines and biomarkers;   The impact of 2 dosing regimens of benralizumab on sputum differential cell count (subset of patients) in the terms of assessment of eosinophil progenitor cells;   The effect of 2 dosing regimens of benralizumab on blood biomarkers in the terms of quantification of serum biomarkers.;   The impact of 2 dosing regimens of benralizumab on lung function as assessed thru body plethysmography (subset of patients) in the terms of Total Lung Capacity (TLC);   The impact of 2 dosing regimens of benralizumab on lung function as assessed thru body plethysmography (subset of patients) in the terms of Residual Volume (RV);   The impact of 2 dosing regimens of benralizumab on lung function as assessed thru body plethysmography (subset of patients) in the terms of Vital Capacity (VC);   The impact of 2 dosing regimens of benralizumab on lung function as assessed thru body plethysmography (subset of patients) in the terms of Inspiratory Capacity (IC);   The impact of 2 dosing regimens of benralizumab on lung function as assessed thru body plethysmography (subset of patients) in the terms of Functional Residual Capacity (FRC)